

Attorney Docket No. 6413.204-US  
Ebdrup et al.  
Serial No. 10/614,233 Filed July 7, 2003

### RESPONSE

The examiner states in the Office Action Summary that claims numbered 1-5 and 7-66 are pending in the application; claims numbered 1-3, 8-30, 33, 34 and 36-61 are allowed; claims numbered 4, 5, 7, 31, 32, 35 and 62-66 are rejected; and claims numbered 4 and 7 are objected to.

(1) The examiner has objected to claims numbered 4 and 7 because they fail to conclude with a period.

Applicant has amended claims numbered 4 and 7 to add a period to the end of the claims.

Applicant respectfully requests reconsideration and withdrawal of the objection to claims numbered 4 and 7.

(2) The examiner has rejected claims numbered 4, 5 and 7 under 35 U.S.C. §112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Specifically, the first appearing structure in claim 4, the P, Se and Ge atoms of claim 5, and the fused ring system depicted in claim 7 each fail to have clear antecedent basis in claim 1.

Applicant has amended claim number 1 to correctly set forth the antecedent basis for claims numbered 4, 5 and 7.

Applicant respectfully requests reconsideration and withdrawal of the rejection to claims numbered 4, 5 and 7 under 35 U.S.C. §112, second paragraph.

(3) The examiner has rejected claims numbered 31 and 32 under 35 U.S.C. §102(a) as being anticipated by either Holmes-Farley et al. (U.S. Patent Application Publication 2003/0064963) or Henderson et al. (U.S. Patent Application Publication 2002/012832).

Applicant has amended claim number 31 to exclude the boron compounds of the references.

Applicant respectfully requests reconsideration and withdrawal of the rejection to claims numbered 31 and 32 under 35 U.S.C. §102(a).

Attorney Docket No. 6413.204-US  
Ebdrup et al.  
Serial No. 10/614,233 Filed July 7, 2003

(4) The examiner has rejected claims numbered 35 and 62-66 under 35 U.S.C. §103(a) as being unpatentable over either Holmes-Farley et al. (U.S. Patent Application Publication 2003/0064963) or Henderson et al. (U.S. Patent Application Publication 2002/012832).


Applicant has amended claim number 31 to exclude the boron compounds of the references. Claim 35 depends from claim 31, and claims numbered 62-66 depend from claim 32, which depends from claim 31.

Applicant respectfully requests reconsideration and withdrawal of the rejection to claims numbered 35 and 62-66 under 35 U.S.C. §103(a).

Support for the amendments made herein can be found in the specification as originally filed on page 7, lines 8-13, and page 9, lines 25-27.

Applicant believes the claims are in condition for allowance. The examiner is hereby invited to contact the undersigned by telephone if he deems the claims have *not* been placed in condition for allowance, or if there are any questions concerning this amendment or application. Applicant respectfully requests that a timely Notice of Allowance be issued in this case.

Respectfully submitted,



Date: January 18, 2005

Rosemarie R. Wilk-Orescan  
Registration Number 45,220  
Novo Nordisk® Inc.  
100 College Road West  
Princeton, NJ 08540  
(609) 987-5969

Use the following customer number for all correspondence regarding this application.

**23650**

PATENT TRADEMARK OFFICE